Filing identity and reporting period
The supplied filing is MEI Pharma, Inc.’s Form 10-Q for the quarter ended March 31, 2024 (fiscal third quarter), filed May 9, 2024. This does not match the request metadata identifying Lite Strategy, Inc. and 2022 Q3; verify that this is the intended filing before relying on the summary.
MEI Pharma is a clinical-stage oncology company. Its stated pipeline includes voruciclib and ME-344. The financial statements are unaudited and amounts below are in U.S. dollars.
Financial results and liquidity
| Metric | Three months ended March 31 | Nine months ended March 31 |
|---|---|---|
| Revenue, 2024 | $0 | $65.3 million |
| Revenue, 2023 | $5.9 million | $47.4 million |
| Operating expenses, 2024 | $9.8 million | $31.8 million |
| Net income (loss), 2024 | ($9.1 million) | $36.2 million |
| Net income (loss), 2023 | ($15.4 million) | ($21.8 million) |
- Nine-month 2024 revenue included $64.5 million of noncash collaboration revenue recognized after termination of the Kyowa Kirin (KKC) agreement. It should not be interpreted as recurring sales or equivalent cash receipts.
- Quarterly R&D expense was $5.2 million, down 65% year over year; quarterly G&A was $4.6 million, down 36%. No gross margin is presented, and the quarter had no revenue.
- For the nine months, operating cash used was $32.5 million, versus $41.2 million in the prior-year period. Net income did not translate into operating cash generation, largely because recognition of deferred revenue was noncash.
- At March 31, 2024, cash and cash equivalents were $2.4 million and short-term U.S. government investments were $54.2 million, totaling $56.6 million. Cash alone fell from $16.9 million at June 30, 2023.
- Total assets were $71.3 million; total liabilities were $20.2 million, including $11.7 million of operating lease liabilities. The filing reports no borrowings or other financial debt.
- Stockholders’ equity was $51.0 million. The company had 6.663 million common shares outstanding. It paid a $11.7 million special dividend in December 2023.
Material changes and notable items
- KKC terminated the global zandelisib agreement in July 2023. MEI regained global rights, subject to limited compassionate-use provisions, and recognized the remaining $64.5 million deferred revenue in the September 2023 quarter.
- Reduced zandelisib activity and workforce reductions drove much of the year-over-year decline in R&D spending. ME-344 R&D costs increased, including clinical and manufacturing costs.
- The nine-month 2024 profit contrasts with a year-earlier loss chiefly because of the one-time KKC revenue recognition. The prior-year period also included a $1.6 million noncash gain from warrant-liability revaluation.
- The company established a $25 million at-the-market offering program in February 2024; no shares had been sold under it by March 31.
Outlook, management commentary, and risks
- Management said existing cash and investments should fund obligations and operations for at least 12 months from issuance of the statements. It expects operating losses and negative operating cash flow for the foreseeable future and expects R&D spending to increase. Future capital may be needed; access to financing is not assured.
- In April 2024, the Board prioritized voruciclib development and supported developing a new ME-344 formulation for a Phase 1 study. The Board also decided not to pursue the potential second capital return of up to $9.33 million under the cooperation agreement, citing preservation of resources and runway.
- Voruciclib is being studied with venetoclax in a Phase 1 trial for relapsed or refractory AML. April 2024 reported early responses and tolerability findings, but the study is ongoing and the maximum tolerated dose had not been established. Management expected additional trial data during the rest of calendar 2024.
- For ME-344 plus bevacizumab, the first cohort of a Phase 1b metastatic colorectal cancer study exceeded its prespecified threshold to allow a second cohort, but the company chose not to open that cohort. The company is pursuing a new formulation; its timing, cost, and clinical prospects remain uncertain.
- Key risks include clinical-trial failure or delay, regulatory uncertainty, manufacturing and formulation challenges, the need for additional capital, reliance on third parties, and the possibility that candidates never become commercially viable. The filing reports no material changes to the risk factors in the 2023 annual report and no pending litigation believed likely to have a material adverse effect.
- Management reported effective disclosure controls as of March 31, 2024 and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the filing identity and period: the source is MEI Pharma’s March 31, 2024 10-Q, not the company and period in the request metadata.
- Assess liquidity using cash plus investments, operating cash use, and the one-time dividend; the reported 12-month runway is management’s estimate, not a guarantee.
- Separate the $64.5 million KKC termination-related noncash revenue from recurring revenue and cash generation.
- Review subsequent voruciclib and ME-344 trial updates, including efficacy, safety, enrollment, formulation plans, and associated spending.
- Monitor potential financing and dilution, including use of the ATM program, and the company’s decision to forgo the additional capital return.